Literature DB >> 3263405

Multiple organ failure during interleukin-2 administration and LAK cells infusion.

J P Sculier1, D Bron, N Verboven, J Klastersky.   

Abstract

Adoptive immunotherapy is a new promising treatment for cancer but is associated with severe toxicity mainly related to a capillary leak syndrome. We report the case of a patient with metastatic hypernephroma, who had many complications such as coma, renal failure, pulmonary edema, life-threatening acidosis, cardiac arrhythmias and venous thrombosis. Critical care specialists should be aware of this type of cancer therapy because of multiple side effects requiring ICU supportive care.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263405     DOI: 10.1007/bf00256776

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  5 in total

1.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

2.  Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

Authors:  A Belldegrun; D E Webb; H A Austin; S M Steinberg; D E White; W M Linehan; S A Rosenberg
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

3.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

4.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

5.  Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

Authors:  M Z Papa; J T Vetto; S E Ettinghausen; J J Mulé; S A Rosenberg
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

  5 in total
  6 in total

1.  Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer.

Authors:  D Diana; J P Sculier
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy.

Authors:  T Darville; B Giroir; R Jacobs
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

3.  Renal effects of continuous infusion of recombinant interleukin-2 in children.

Authors:  P Cochat; D Floret; E Bouffet; C R Francks; M C Favrot; T Philip; L David
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

4.  Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.

Authors:  J P Wersäll; G Masucci; A L Hjelm; P Ragnhammar; J Fagerberg; J E Frödin; K Merk; C Lindemalm; K Ericson; B Kalin
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 5.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

Review 6.  Intensive care and oncology.

Authors:  J P Sculier
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.